Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 2
Development Phase
1
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
Tazemetostat Phase 3 Results Expected
Tazemetostat • Diffuse Large B-cell Lymphoma (DLBCL)
Target Indication
Diffuse Large B-cell Lymphoma (DLBCL)
Clinical Trial
NCT02875548Last updated: 12/4/2025